MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 14; no. 2; p. 130
• Main Authors: Chen, Chao-Ju, Liu, Yu-Peng
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.02.2021; MDPI
• Subjects: Breast cancer; Cardiovascular disease; Cell adhesion & migration; Chronic obstructive pulmonary disease; Drug resistance; EGFR-TKI resistance; Epidermal growth factor; Kinases; Ligands; Lung cancer; MERTK; Mutation; non-small cell lung cancer; Patients; Review; non-small cell lung cancer; EGFR-TKI resistance; MERTK

Epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) are currently the most effective treatment for non-small cell lung cancer (NSCLC) patients, who carry primary EGFR mutations. However, the patients eventually develop drug resistance to EGFR-TKIs after approximately one year. In addition...